Aker Biomarine AS (AKBM) - Net Assets
Based on the latest financial reports, Aker Biomarine AS (AKBM) has net assets worth Nkr149.50 Million NOK (≈ $15.73 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr387.00 Million ≈ $40.72 Million USD) and total liabilities (Nkr237.50 Million ≈ $24.99 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check AKBM cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr149.50 Million |
| % of Total Assets | 38.63% |
| Annual Growth Rate | 11.27% |
| 5-Year Change | -53.4% |
| 10-Year Change | N/A |
| Growth Volatility | 83.55 |
Aker Biomarine AS - Net Assets Trend (2016–2024)
This chart illustrates how Aker Biomarine AS's net assets have evolved over time, based on quarterly financial data. Also explore AKBM total assets for the complete picture of this company's asset base.
Annual Net Assets for Aker Biomarine AS (2016–2024)
The table below shows the annual net assets of Aker Biomarine AS from 2016 to 2024. For live valuation and market cap data, see Aker Biomarine AS (AKBM) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr173.90 Million ≈ $18.30 Million |
-52.55% |
| 2023-12-31 | Nkr366.50 Million ≈ $38.57 Million |
-3.22% |
| 2022-12-31 | Nkr378.70 Million ≈ $39.85 Million |
+2.25% |
| 2021-12-31 | Nkr370.37 Million ≈ $38.97 Million |
-0.75% |
| 2020-12-31 | Nkr373.17 Million ≈ $39.27 Million |
+141.46% |
| 2019-12-31 | Nkr154.55 Million ≈ $16.26 Million |
-13.57% |
| 2018-12-31 | Nkr178.81 Million ≈ $18.82 Million |
+201.56% |
| 2017-12-31 | Nkr59.30 Million ≈ $6.24 Million |
-19.90% |
| 2016-12-31 | Nkr74.03 Million ≈ $7.79 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Aker Biomarine AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25000100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Nkr75.90 Million | 43.75% |
| Other Components | Nkr493.90 Million | 284.67% |
| Total Equity | Nkr173.50 Million | 100.00% |
Aker Biomarine AS Competitors by Market Cap
The table below lists competitors of Aker Biomarine AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lonkey Industrial Co Ltd Guangzhou
SHE:000523
|
$926.62 Million |
|
Matrix Design Co. Ltd. A
SHE:301365
|
$926.63 Million |
|
Guangzhou Metro Design And Research
SHE:003013
|
$927.07 Million |
|
Zhejiang Cayi Vacuum Container Co. Ltd.
SHE:301004
|
$927.26 Million |
|
Tianjin Economic-technological Development Area Co Ltd
SHE:000652
|
$926.31 Million |
|
Vaudoise Assurances Holding SA
SW:VAHN
|
$925.74 Million |
|
Plejd AB (publ)
F:3CA
|
$925.60 Million |
|
Dazzle Fashion Co Ltd
SHG:603587
|
$925.46 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aker Biomarine AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 366,600,000 to 173,500,000, a change of -193,100,000 (-52.7%).
- Net income of 182,400,000 contributed positively to equity growth.
- Dividend payments of 373,200,000 reduced retained earnings.
- Other factors decreased equity by 2,300,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr182.40 Million | +105.13% |
| Dividends Paid | Nkr373.20 Million | -215.1% |
| Other Changes | Nkr-2.30 Million | -1.33% |
| Total Change | Nkr- | -52.67% |
Book Value vs Market Value Analysis
This analysis compares Aker Biomarine AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 50.73x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 118.79x to 50.73x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | Nkr0.85 | Nkr100.40 | x |
| 2017-12-31 | Nkr0.68 | Nkr100.40 | x |
| 2018-12-31 | Nkr2.04 | Nkr100.40 | x |
| 2019-12-31 | Nkr1.76 | Nkr100.40 | x |
| 2020-12-31 | Nkr4.26 | Nkr100.40 | x |
| 2021-12-31 | Nkr4.23 | Nkr100.40 | x |
| 2022-12-31 | Nkr4.32 | Nkr100.40 | x |
| 2023-12-31 | Nkr4.18 | Nkr100.40 | x |
| 2024-12-31 | Nkr1.98 | Nkr100.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aker Biomarine AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 105.13%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 91.66%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 2.23x
- Recent ROE (105.13%) is above the historical average (5.89%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -2.78% | -1.78% | 0.41x | 3.77x | Nkr-9.46 Million |
| 2017 | -29.96% | -14.31% | 0.33x | 6.36x | Nkr-23.69 Million |
| 2018 | -0.57% | -0.66% | 0.36x | 2.41x | Nkr-18.90 Million |
| 2019 | -15.37% | -9.65% | 0.36x | 4.48x | Nkr-39.20 Million |
| 2020 | -1.46% | -1.89% | 0.41x | 1.88x | Nkr-42.78 Million |
| 2021 | -2.16% | -3.06% | 0.35x | 2.05x | Nkr-45.05 Million |
| 2022 | 2.64% | 3.61% | 0.34x | 2.18x | Nkr-27.87 Million |
| 2023 | -2.43% | -2.65% | 0.41x | 2.26x | Nkr-45.56 Million |
| 2024 | 105.13% | 91.66% | 0.51x | 2.23x | Nkr165.05 Million |
Industry Comparison
This section compares Aker Biomarine AS's net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $5,223,167,000
- Average return on equity (ROE) among peers: -93.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aker Biomarine AS (AKBM) | Nkr149.50 Million | -2.78% | 1.59x | $926.58 Million |
| Hofseth Biocare ASA (HBC) | $32.55 Million | -307.85% | 4.94x | $55.08 Million |
| Lerøy Seafood Group ASA (LSG) | $5.96 Billion | 8.06% | 0.97x | $2.85 Billion |
| Orkla ASA (ORK) | $9.67 Billion | 18.11% | 1.74x | $11.80 Billion |
About Aker Biomarine AS
Aker BioMarine ASA, a biotech innovator, develops and supplies krill-derived products for consumer health and wellness worldwide. It operates through three segments: Human Health Ingredients (HHI), Consumer Health Products, and Emerging Business. The Human Health Ingredients segment sells B2B krill oil supplements for humans under the Superba Krill brand; supplements for brain health under the LY… Read more